Molecular Imaging of Brain Inflammation in Depressive Disorders (DiME)

Lawson Health Research Institute

Status: Completed

Conditions: Depressive Disorder, Major; Positron-Emission Tomography

Study type: Observational

Funder types: Other

Identifiers

NCT02983318

100128

Details and patient eligibility

About

In a number of neuropsychiatric disorders such as depression, both brain inflammation and glutamate mediated excitotoxicity (cell death through over-activated stimulation) are suspected to play a key role. It is difficult, if not impossible, to determine the potential destructiveness of the inflammatory response seen in disease states by studying the brain's inflammatory cells (microglia) activity in isolation. The investigators are proposing to develop the means to concurrently study inflammatory response (i.e., microglial activity) and its potentially devastating consequence (i.e., glutamate excitotoxicity) across the entire brain in order to establish the importance of inflammation. In this study the investigators propose a phased clinical study whereby the early-phase involves the development of our capacity to study inflammation-mediated damage to brain cells, followed by a feasibility study in patients with clinical depression that tests whether concurrent inflammation and glutamate excess could be measured in key brain regions associated with a depressed mood state.

Enrollment: 20 patients

Sex: All

Ages: 19 to 105 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• screening form for MRI/PET is satisfactory after being reviewed by a radiologist
• diagnosed with depression or healthy control participants with no present mental health disorder
• Good general health with no diseases expected to interfere with the study
• Subject is not pregnant, lactating, or of childbearing potential (must be practicing effective form of birth control)
• Patient and healthy controls must not have an infection or an autoimmune disorder or persistent inflammation.

Exclusion criteria

• Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol
• use of Investigational agents within last month

Trial design

20 participants in 1 patient group

PET/MRI using 18[F]EPPA ligand

Description:

given experimental ligand FEPPA during MRI/PET scan to identify glutamate activity in the brain using FEPPA ligand